Title: Capromab
CAS Registry Number: 151763-64-3
CAS Name: Anti-(human prostatic carinoma cell) immunoglobulin G1 (mouse monoclonal 7E11-C5.3 g1-chain) disulfide with mouse monoclonal 7E11-C5.3 light chain, dimer
Literature References: Murine monoclonal antibody directed against prostate specific membrane antigen (PSMA), a transmembrane glycoprotein expressed by prostate epithelium. Designed for the detection of primary and metastatic prostate carcinoma. Prepn: J. S. Horoszewicz et al., Anticancer Res. 7, 927 (1987); idem, US 5162504 (1992 to Cytogen). Characterization and specificity of immunoconjugate: A. D. Lopes et al., Cancer Res. 50, 6423 (1990). Diagnostic use of labeled form in metastatic prostate cancer: M. J. Manyak et al., Urology 54, 1058 (1999). Review of clinical studies: R. T. Maguire et al., Cancer 72, 3453-3462 (1993); and pharmacology: H. M. Lamb, D. Faulds, Drugs Aging 12, 293-304 (1998). Review of diagnostic use: M. K. Haseman et al., Cancer Biother. Radiopharm. 15, 131-140 (2000).
Derivative Type: Capromab pendetide
CAS Registry Number: 145464-28-4
Additional Names: 7E11-C5.3-GYK-DTPA; 7E11-C5.3-glycyl-tyrosyl-(N-e-diethylenetriaminepentaacetic acid)-lysine
Manufacturers' Codes: CYT-356
Trademarks: ProstaScint (Cytogen)
Literature References: Monoclonal antibody conjugated to a linker-chelator to enable radiolabeling. Prepd as hydrochloride and labeled with Indium 111In immediately before administration.
Therap-Cat: 111In-labeled form as diagnostic aid (radioactive tumor-targeting agent).
Caproyl Chloride Caprylene Caprylic Acid Caprylic Aldehyde CAPS

Indium (111In) capromab pendetide?
Monoclonal antibody
Type Whole antibody
Source Mouse
Target prostatic carcinoma cells
Clinical data
Trade names Prostascint
Legal status  ?
CAS number 151763-64-3 N (capromab)
148805-91-8 (pendetide)
ATC code V09IB04
Chemical data
Formula  ?
 N (what is this?)  (verify)

Indium (111In) capromab pendetide (trade name Prostascint) is used to image the extent of prostate cancer.[1] Capromab is a mouse monoclonal antibody which recognizes prostate specific membrane antigen (PSMA) from prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA.[2] Pendetide acts as a chelating agent for the radionuclide indium-111. Following an intravenous injection of Prostascint, imaging is performed using single photon emission computed tomography (SPECT).[1]

Early trials with yttrium (90Y) capromab pendetide were also conducted.[3]